PRAX News

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor